Analytical Data
-
Gene name
HLA-A*0301 KRAS G12V Complex
-
简介
HLA-A*0301 collaborates with B2M to present viral and tumor peptides that direct CD8-positive T cells to respond against infected or transformed cells. It can also present self-peptides to avoid self-reaction. HLA-A*0301 KRAS G12V Complex Protein, Human (HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A*0301 and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with C-Avi, C-His labeled tag and VVGAVGVGK peptide. HLA-A*0301 KRAS G12V Complex Protein, Human (HEK293, His-Avi), has molecular weight of 55-60 kDa.
- Application
-
Alternative Names
MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
NP_002107.3 (G25-T305)&P61769
-
Expression Region
NP_002107.3 (G25-T305)&P61769 (I21-M119)&VVGAVGVGK
-
Molecular Weight
55-60 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the HLA-A*0301 KRAS G12V complex recombinant protein is pivotal due to the critical role of KRAS mutations in cancer, particularly in pancreatic, colorectal, and lung cancers. The KRAS G12V mutation is one of the most common oncogenic alterations, driving tumorigenesis and contributing to cancer progression. Understanding how this specific mutation interacts with the major histocompatibility complex (MHC) molecule HLA-A*0301 is essential for advancing immunotherapy strategies. HLA-A*0301 is known for its ability to present specific peptide fragments derived from proteins, including mutated oncogenes, to T cells, thereby eliciting an immune response. By characterizing the KRAS G12V peptide complexed with HLA-A*0301, researchers aim to uncover the mechanisms of immune recognition and response to cancer cells harboring this mutation. This research has the potential to inform the development of personalized cancer vaccines and adoptive T cell therapies, targeting tumors expressing KRAS G12V. Moreover, by elucidating the structural and functional aspects of the HLA-A*0301 KRAS G12V complex, scientists can enhance understanding of immune evasion tactics used by cancer cells, which is vital for improving existing therapeutic modalities and discovering new approaches for cancer treatment.
